SUPerficial ENDometriosis In Magnetic Resonance Imaging
NCT ID: NCT06195280
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2025-04-30
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PET/MRI for Evaluation of Endometriosis
NCT06377553
ENDOMED: Evaluation of the Evolution of Endometriosis Lesions on Imaging Under Medical Treatment
NCT05722314
Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions
NCT07053982
Preoperative Staging of Endometriosis With MRI
NCT01939535
Exploratory Study of the Interest of MRI Susceptibility Weighted Imaging for the Pre-operative Assessment of Pelvic Endometriosis Extent
NCT03186820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The duration of the patient's participation in the study is a maximum of 15 months depending on the length of the screening period and the time between Magnetic Resonance Imaging and laparoscopy.
After selection, the investigator will check the patient's eligibility and offer her the study. If she accepts and signs the informed consent form, the patient will have an exploratory pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.
After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
superficial endometriosis
Endometriosis is a chronic, estrogen-dependent inflammatory disease secondary to tissue growth outside the uterine cavity, affecting approximately 10% of women of childbearing age.
Magnetic resonance imaging, 3DT1 sequence
The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.
Laparoscopy
After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnetic resonance imaging, 3DT1 sequence
The patient will have an exploration pelvic Magnetic Resonance Imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product.
Laparoscopy
After Magnetic Resonance Imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-menopausal patient;
* Patient scheduled for exploratory laparoscopy;
* Patient requiring a preoperative pelvic MRI
* Patient having been informed and having signed an informed consent form.
Exclusion Criteria
* Contraindications to anesthesia for exploratory laparoscopy;
* Contraindication to surgery following the findings of magnetic resonance imaging results;
* Patient with endometrioma \> 4 cm;
* Patient with known deep endometriosis;
* Patient uncooperative with protocol requirements or unable to attend the center for scheduled visits;
* Pregnant woman or woman of childbearing age, without effective contraception or breastfeeding;
* Patient participating in another clinical trial, or during a period of exclusion from another clinical trial;
* Patient under guardianship, under curatorship or subject to legal protection, persons deprived of liberty by a judicial or administrative decision, persons subject to psychiatric care and admitted to a health or social establishment;
* Patient not beneficiary of a social security system
* Patient under State Medical Aid.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Euraxi Pharma
INDUSTRY
GCS Ramsay Santé pour l'Enseignement et la Recherche
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinique Blomet
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A01336-39
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.